0001104659-20-007323 8-A12B 1 20200128 20200128 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 8-A12B 34 001-39202 20551312 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 8-A12B 1 tm199635-12_8a12b.htm FORM 8-A12B

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

ANNOVIS BIO, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware     26-2540421
(State or other jurisdiction of
incorporation or organization)
    (I.R.S. Employer
Identification Number)
       

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312

    19312
(Address of principal executive offices)     (Zip Code)

 

 

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

 

Name of each exchange on which

each class is to be registered

     
Common Stock, par value $0.0001 per share   NYSE American

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

 

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-232529

 

Securities to be registered pursuant to Section 12(g) of the Act: None.

 

 

 

 

 

Item 1. Description of Registrant’s Securities to be Registered.

 

Annovis Bio, Inc., a Delaware corporation (the “Registrant”), hereby incorporates by reference the description of its common stock, par value $0.0001 per share, to be registered hereunder contained under the heading “Description of Our Capital Stock” in the Registrant's Registration Statement on Form S-1 (File No. 333-232529), as initially filed publicly with the Securities and Exchange Commission (the "Commission") on July 3, 2019, as amended (the “Registration Statement”), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.

 

Item 2. Exhibits.

 

In accordance with the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on NYSE American and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Date: January 28, 2020  ANNOVIS BIO, INC.
    
   By: /s/ Maria Maccecchini
   Name: Maria Maccecchini
   Title: President and Chief Executive Officer